- Commercial revenue increased approximately 5.8% to $11.1 million compared to the same period in 2023
- Gross profit margin of 86.4%
- Launched PermeaDerm, a co-branded biosynthetic wound matrix, in the U.S. on March 23, 2024
Future Milestones
- RECELL GO, a device which provides consistent disaggregation of skin to produce RECELL Spray-On Skin Cells, is currently undergoing a 180-day interactive review by the U.S. Food and Drug Administration under the Breakthrough Devices Program; the 180-day period will end on May 30, 2024
- Plan to submit a PMA supplement for RECELL GO mini, which is designed to address smaller wounds. This submission will fall under the Breakthrough Device designation, which has been granted to RECELL for burns, RECELL for full-thickness skin defects, RECELL for repigmentation of stable depigmented vitiligo lesions, and RECELL GO
- Expect to submit both our post-market study (TONE) treating patients with stable vitiligo, and separate health economics study for publication by year-end
Financial Guidance
- Commercial revenue for the second quarter 2024 is expected to be in the range of $14.3 to $15.3 million
- Commercial revenue for the full-year 2024 is expected to be in the lower end of our previously provided guidance range of $78.5 to $84.5 million, reflecting growth of approximately 57% at the lower end of the range over the full-year 2023
- Expect to achieve previously given guidance of cashflow break even and GAAP profitability no later than the third quarter of 2025
- Forums
- ASX - By Stock
- AVH
- Ann: AVITA Medical to Announce First Quarter 2024 Results
Ann: AVITA Medical to Announce First Quarter 2024 Results, page-25
-
- There are more pages in this discussion • 170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.08 |
Change
0.050(1.65%) |
Mkt cap ! $217.1M |
Open | High | Low | Value | Volume |
$3.03 | $3.15 | $3.03 | $300.9K | 97.16K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10 | $3.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.14 | 73 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10 | 3.070 |
1 | 10 | 3.060 |
1 | 3000 | 3.030 |
1 | 330 | 3.020 |
4 | 23339 | 3.000 |
Price($) | Vol. | No. |
---|---|---|
3.140 | 73 | 2 |
3.150 | 17833 | 4 |
3.160 | 553 | 2 |
3.170 | 1000 | 1 |
3.180 | 3000 | 1 |
Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
Featured News
BM8
Learn of the ASX-listed company that is well-placed to respond to the future global energy demand
SBW
Shekel Brainweigh reports a 50% revenue increase in its Retail Innovation suite and delivers the first batch of 20 Smart Bays to Hitachi as part of a larger order
AVH (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online